Q2 2026 Novavax Inc Earnings Call Transcript

Aug 6, 2026 / 12:30 PM GMT

Release Date Price: $7.74 (+0.52%)

Transcript 8-K10-Q

Key Points

Positve

Novavax Inc (NVAX) has secured licensing or material transfer agreements with 4 of the TOP10 global pharmaceutical companies, including Pfizer, for its Matrix-M adjuvant, covering over 30 areas of exploration in infectious disease and oncology.
The Sanofi partnership is progressing well, with Sanofi confirming its intent to be a first mover in the combination COVID-19/influenza vaccine market and entering advanced regulatory discussions for a Phase 3 study, which would trigger a $125 million milestone payment.
The company is seeing strong momentum in oncology, executing an MTA with a leading global pharma company in immuno-oncology and generating encouraging preclinical data supporting Matrix-M's potential in therapeutic cancer vaccines.
Novavax Inc (NVAX) is on track to achieve an approximately 90% reduction in operating expenses from peak, with a 36% decrease in combined R&D and SG&A expenses in Q2 2026, and is reiterating its goal of reaching non-GAAP profitability as early as 2028.
The company increased its full-year 2026 revenue guidance to between $235 million and $275 million, driven by strong demand for Matrix-M from commercial partners like Takeda and Serum Institute, and expects to extend its cash runway into 2029 with the anticipated $75 million manufacturing tech transfer milestone from Sanofi.

Negative

Novavax Inc (NVAX) reported a net loss of $53 million in Q2 2026, with total revenue of $57 million, a significant decline from $239 million in the prior year, largely due to the absence of one-time milestone payments.
The company's future profitability is heavily dependent on the timing of Sanofi's combination vaccine launch, which remains uncertain and outside of Novavax's direct control.
Novavax Inc (NVAX) faces potential non-cash fixed asset write-offs of up to $35 million in 2027 as part of its plan to reduce its operating footprint by over 50%.
The company is reducing its partner R&D reimbursements guidance by $10 million for 2026, reflecting lower expected reimbursements as it delivers efficiently on partner-related obligations.
Novavax Inc (NVAX) remains reliant on a few key partners, particularly Sanofi, for significant milestone payments and commercial success, and the company cannot provide guidance on partner activities, creating uncertainty for investors.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

NVAX.OQ - Novavax, Inc.
Q2 2026 Novavax Inc Earnings Call
Aug 06, 2026 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you for standing by everyone, my name is Jim, and I'll be your conference operator for today.

I would like to welcome everyone to the Novavax second quarter 2026.

Financial results and operational highlights conference call.

All lines have been placed on a mute to prevent any background noise after today's speakers' remarks, there will be a question-and-answer session if you would like to ask a question during that time, simply press star, followed by the number 1 on your telephone keypad, and if you would like to withdraw your questions, simply press star and 1 again.

Thank you.

It's now my pleasure to turn the floor over to as a man, you may begin.

Good morning and thank you all for

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.